Clinical anti-lymphoma activity and toxicity of T cells expressing a novel anti-CD19 chimeric antigen receptor with fully-human variable regions.

Jennifer N. Brudno,Steven Hartman,Stefania Pittaluga,David F. Stroncek,Norris Lam,Jennifer A. Kanakry,Steven Z. Pavletic,Lekha Mikkilineni,Mohammadhadi Bagheri,Mark Roschewski,Robert M. Dean,Jeremy J. Rose,Rashmika Patel,Brenna Hansen,Ronald E. Gress,James N. Kochenderfer

Clinical anti-lymphoma activity and toxicity of T cells expressing a novel anti-CD19 chimeric antigen receptor with fully-human variable regions.

2018

Jennifer N. Brudno
Steven Hartman
Stefania Pittaluga
David F. Stroncek
Norris Lam
Jennifer A. Kanakry
Steven Z. Pavletic
Lekha Mikkilineni
Mohammadhadi Bagheri
Mark Roschewski
Robert M. Dean
Jeremy J. Rose
Rashmika Patel
Brenna Hansen
Ronald E. Gress
James N. Kochenderfer

3052Background: T cells expressing chimeric antigen receptors (CARs) targeting CD19 have powerful activity against B-cell lymphoma. A limitation to CAR T-cell therapy for lymphoma is occurrence of ...

Keywords:

Lymphoma
Chimeric antigen receptor
Pathology
Toxicity
Cancer research
Medicine
CD19
anti cd19

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations